More importantly, CAFs also promote the CSC phenotype and chemoresistance development in ovarian tumor models (145, 146) and several studies have demonstrated that CD44 and STAT3 signaling pathways are involved in CAF-mediated therapy resistance. This evidence concerns the gene CD44 and ovarian neoplasm.